Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Gene Therapeutics & RNAi

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1420377

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1420377

MicroRNA Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

PUBLISHED:
PAGES: 273 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PPT Slides/PDF & Excel (Enterprise License)
USD 4995

Add to Cart

Description

Table of Contents

The global microRNA market is experiencing significant growth and transformation, characterized by intense competition among various companies, including domestic players, which has led to a highly fragmented landscape. Thermo Fisher Scientific Inc. claimed the top position in the global microRNA market in 2016, commanding a substantial share of revenue due to its extensive product portfolio.

Market Leader with Comprehensive Solutions

Thermo Fisher Scientific Inc. has secured a substantial market share by offering a wide range of miRNA reagents and the essential hardware for conducting miRNA assays. Additionally, the company has introduced microRNA products tailored to the animal health and agriculture sector, further solidifying its position as a market leader.

Illumina Inc. and NGS Advancements

Illumina Inc. holds the second position in the global microRNA market, driven by its microarray kits and library preparation kits for miRNA analysis. The increasing adoption of Next-Generation Sequencing (NGS) for miRNA research has bolstered Illumina's market presence, offering unmatched efficacy in discovering and detecting miRNA molecules.

Agilent Technologies, Inc. Innovates

Agilent Technologies, Inc. follows closely behind Illumina Inc. with a market share of 7.5%. The company manufactures microarrays and has recently introduced an innovative application for studying miRNAs by combining the miRNA methodology with SurePrint inkjet synthesis technology.

PCR Technologies Advancing Precision

Advancements in PCR technologies have paved the way for more accurate results in miRNA research. The market now offers various PCR techniques:

  • Endpoint PCR: Amplifying a target for future use, such as DNA sequencing or microsatellite analysis, with gel electrophoresis for product confirmation.
  • Quantitative PCR (qPCR): Provides detailed quantitation of the material produced, enabling scientists to monitor each cycle of the reaction through fluorescence markers.
  • Digital PCR: Splits PCR reactions into thousands or millions of partitions, each containing zero or one copy of the target DNA, allowing for precise endpoint reactions.

Diversified Product Offerings for Industry Verticals

To gain a competitive edge, companies are diversifying their product offerings to cater to different industry verticals. The life sciences and biotechnology sector, once dominated by North America and Europe, is experiencing a shift towards Asia Pacific, with countries like India attracting outsourcing of biotech projects. Initiatives by governments to support domestic biotechnology industries are further driving this trend.

PCR Based Arrays Lead the Way

PCR-based arrays segment has dominated the global microRNA market in terms of revenue, with a projected continuation of this trend. This segment is expected to be the most lucrative among all end-users, with an attractiveness index of 1.6. Additionally, next-generation sequencing is gaining traction, representing a significant portion of the market and poised to expand at a CAGR of 8.1% over the forecast period.

Market Segmentation

Assay Type

  • PCR-based Assay
  • miRNA Arrays
  • Next Generation Sequencing (NGS)
  • Immunoassay

Fluorescent Assays

Colorimetric Assays

Chemiluminescent Assays

Application

  • Clinical Diagnostics
  • Research

End User

  • Academic and Research Institutes
  • Biopharmaceutical Companies
  • Contract Research Organizations
  • Diagnostic Centers

Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global MicroRNA Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global MicroRNA Market Outlook, 2018 - 2031

  • 3.1. Global MicroRNA Market Outlook, by Assay Type, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. PCR-based Assay
      • 3.1.1.2. miRNA Arrays
      • 3.1.1.3. Next Generation Sequencing (NGS)
      • 3.1.1.4. Immunoassay
        • 3.1.1.4.1. Fluorescent Assays
        • 3.1.1.4.2. Colorimetric Assays
        • 3.1.1.4.3. Chemiluminescent Assays
  • 3.2. Global MicroRNA Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Clinical Diagnostics
      • 3.2.1.2. Research
  • 3.3. Global MicroRNA Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Academic and Research Institutes
      • 3.3.1.2. Biopharmaceutical Companies
      • 3.3.1.3. Contract Research Organizations
      • 3.3.1.4. Diagnostic Centers
  • 3.4. Global MicroRNA Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America MicroRNA Market Outlook, 2018 - 2031

  • 4.1. North America MicroRNA Market Outlook, by Assay Type, Value (US$ Bn), 2018 - 2031
      • 4.1.1.1. PCR-based Assay
      • 4.1.1.2. miRNA Arrays
      • 4.1.1.3. Next Generation Sequencing (NGS)
      • 4.1.1.4. Immunoassay
        • 4.1.1.4.1. Fluorescent Assays
        • 4.1.1.4.2. Colorimetric Assays
        • 4.1.1.4.3. Chemiluminescent Assays
  • 4.2. North America MicroRNA Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Clinical Diagnostics
      • 4.2.1.2. Research
  • 4.3. North America MicroRNA Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Academic and Research Institutes
      • 4.3.1.2. Biopharmaceutical Companies
      • 4.3.1.3. Contract Research Organizations
      • 4.3.1.4. Diagnostic Centers
  • 4.4. North America MicroRNA Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 4.4.1.2. U.S. MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 4.4.1.3. U.S. MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
      • 4.4.1.4. Canada MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 4.4.1.5. Canada MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 4.4.1.6. Canada MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe MicroRNA Market Outlook, 2018 - 2031

  • 5.1. Europe MicroRNA Market Outlook, by Assay Type, Value (US$ Bn), 2018 - 2031
      • 5.1.1.1. PCR-based Assay
      • 5.1.1.2. miRNA Arrays
      • 5.1.1.3. Next Generation Sequencing (NGS)
      • 5.1.1.4. Immunoassay
        • 5.1.1.4.1. Fluorescent Assays
        • 5.1.1.4.2. Colorimetric Assays
        • 5.1.1.4.3. Chemiluminescent Assays
  • 5.2. Europe MicroRNA Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Clinical Diagnostics
      • 5.2.1.2. Research
  • 5.3. Europe MicroRNA Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Academic and Research Institutes
      • 5.3.1.2. Biopharmaceutical Companies
      • 5.3.1.3. Contract Research Organizations
      • 5.3.1.4. Diagnostic Centers
  • 5.4. Europe MicroRNA Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.2. Germany MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.4.1.3. Germany MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.4. U.K. MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.5. U.K. MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.4.1.6. U.K. MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.7. France MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.8. France MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.4.1.9. France MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.10. Italy MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.11. Italy MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.4.1.12. Italy MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.13. Turkey MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.14. Turkey MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.4.1.15. Turkey MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.16. Russia MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.17. Russia MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.4.1.18. Russia MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.19. Rest of Europe MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.20. Rest of Europe MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.4.1.21. Rest of Europe MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific MicroRNA Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific MicroRNA Market Outlook, by Assay Type, Value (US$ Bn), 2018 - 2031
      • 6.1.1.1. PCR-based Assay
      • 6.1.1.2. miRNA Arrays
      • 6.1.1.3. Next Generation Sequencing (NGS)
      • 6.1.1.4. Immunoassay
        • 6.1.1.4.1. Fluorescent Assays
        • 6.1.1.4.2. Colorimetric Assays
        • 6.1.1.4.3. Chemiluminescent Assays
  • 6.2. Asia Pacific MicroRNA Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Clinical Diagnostics
      • 6.2.1.2. Research
  • 6.3. Asia Pacific MicroRNA Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Academic and Research Institutes
      • 6.3.1.2. Biopharmaceutical Companies
      • 6.3.1.3. Contract Research Organizations
      • 6.3.1.4. Diagnostic Centers
  • 6.4. Asia Pacific MicroRNA Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.2. China MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 6.4.1.3. China MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.4. Japan MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.5. Japan MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 6.4.1.6. Japan MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.7. South Korea MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.8. South Korea MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 6.4.1.9. South Korea MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.10. India MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.11. India MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 6.4.1.12. India MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.13. Southeast Asia MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.14. Southeast Asia MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 6.4.1.15. Southeast Asia MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America MicroRNA Market Outlook, 2018 - 2031

  • 7.1. Latin America MicroRNA Market Outlook, by Assay Type, Value (US$ Bn), 2018 - 2031
      • 7.1.1.1. PCR-based Assay
      • 7.1.1.2. miRNA Arrays
      • 7.1.1.3. Next Generation Sequencing (NGS)
      • 7.1.1.4. Immunoassay
        • 7.1.1.4.1. Fluorescent Assays
        • 7.1.1.4.2. Colorimetric Assays
        • 7.1.1.4.3. Chemiluminescent Assays
  • 7.2. Latin America MicroRNA Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Clinical Diagnostics
      • 7.2.1.2. Research
  • 7.3. Latin America MicroRNA Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Academic and Research Institutes
      • 7.3.1.2. Biopharmaceutical Companies
      • 7.3.1.3. Contract Research Organizations
      • 7.3.1.4. Diagnostic Centers
  • 7.4. Latin America MicroRNA Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.2. Brazil MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 7.4.1.3. Brazil MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
      • 7.4.1.4. Mexico MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.5. Mexico MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 7.4.1.6. Mexico MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
      • 7.4.1.7. Argentina MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.8. Argentina MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 7.4.1.9. Argentina MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa MicroRNA Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa MicroRNA Market Outlook, by Assay Type, Value (US$ Bn), 2018 - 2031
      • 8.1.1.1. PCR-based Assay
      • 8.1.1.2. miRNA Arrays
      • 8.1.1.3. Next Generation Sequencing (NGS)
      • 8.1.1.4. Immunoassay
        • 8.1.1.4.1. Fluorescent Assays
        • 8.1.1.4.2. Colorimetric Assays
        • 8.1.1.4.3. Chemiluminescent Assays
  • 8.2. Middle East & Africa MicroRNA Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Clinical Diagnostics
      • 8.2.1.2. Research
  • 8.3. Middle East & Africa MicroRNA Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Academic and Research Institutes
      • 8.3.1.2. Biopharmaceutical Companies
      • 8.3.1.3. Contract Research Organizations
      • 8.3.1.4. Diagnostic Centers
  • 8.4. Middle East & Africa MicroRNA Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.2. GCC MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 8.4.1.3. GCC MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.4. South Africa MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.5. South Africa MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 8.4.1.6. South Africa MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.7. Egypt MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.8. Egypt MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 8.4.1.9. Egypt MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.10. Nigeria MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.11. Nigeria MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 8.4.1.12. Nigeria MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa MicroRNA Market by Assay Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa MicroRNA Market by Application, Value (US$ Bn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa MicroRNA Market End User, Value (US$ Bn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Assay Type vs End User Heatmap
  • 9.2. Manufacturer vs End User Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Illumina, Inc.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Assay Type Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. F. Hoffmann-La Roche Ltd
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Assay Type Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Agilent Technologies
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Assay Type Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Bio-Rad Laboratories Inc.
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Assay Type Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. Sigma Aldrich Corp.
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Assay Type Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Qiagen N.V
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Assay Type Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Thermo Fisher Scientific, Inc.
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Assay Type Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. HTG Molecular Diagnostics, Inc.
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Assay Type Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. Bioline GmbH (A Meridian Life Science Company)
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Assay Type Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Rosetta Genomics Ltd.
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Assay Type Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development
    • 9.5.11. Dharmacon, a Horizon Discovery Group Co.
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Assay Type Portfolio
      • 9.5.11.3. Financial Overview
      • 9.5.11.4. Business Strategies and Development
    • 9.5.12. BioVendor - Laboratorni medicina a.s.
      • 9.5.12.1. Company Overview
      • 9.5.12.2. Assay Type Portfolio
      • 9.5.12.3. Financial Overview
      • 9.5.12.4. Business Strategies and Development
    • 9.5.13. Miltenyi Biotec
      • 9.5.13.1. Company Overview
      • 9.5.13.2. Assay Type Portfolio
      • 9.5.13.3. Financial Overview
      • 9.5.13.4. Business Strategies and Development
    • 9.5.14. Kaneka Corporation (Eurogentec)
      • 9.5.14.1. Company Overview
      • 9.5.14.2. Assay Type Portfolio
      • 9.5.14.3. Financial Overview
      • 9.5.14.4. Business Strategies and Development
    • 9.5.15. Abcam Plc
      • 9.5.15.1. Company Overview
      • 9.5.15.2. Assay Type Portfolio
      • 9.5.15.3. Financial Overview
      • 9.5.15.4. Business Strategies and Development
    • 9.5.16. GeneCopoeia, Inc.
      • 9.5.16.1. Company Overview
      • 9.5.16.2. Assay Type Portfolio
      • 9.5.16.3. Financial Overview
      • 9.5.16.4. Business Strategies and Development
    • 9.5.17. Promega Corporation
      • 9.5.17.1. Company Overview
      • 9.5.17.2. Assay Type Portfolio
      • 9.5.17.3. Financial Overview
      • 9.5.17.4. Business Strategies and Development
    • 9.5.18. New England Biolabs, Inc.
      • 9.5.18.1. Company Overview
      • 9.5.18.2. Assay Type Portfolio
      • 9.5.18.3. Financial Overview
      • 9.5.18.4. Business Strategies and Development
    • 9.5.19. NanoString Technologies, Inc.
      • 9.5.19.1. Company Overview
      • 9.5.19.2. Assay Type Portfolio
      • 9.5.19.3. Financial Overview
      • 9.5.19.4. Business Strategies and Development
    • 9.5.20. System Biosciences LLC
      • 9.5.20.1. Company Overview
      • 9.5.20.2. Assay Type Portfolio
      • 9.5.20.3. Financial Overview
      • 9.5.20.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!